Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2010. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.3 million in exchange for committed research services through Dec. 22, 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such product shall no longer be covered by a valid claim of a U.S. or foreign p
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... converters are important devices in spintronics, an electronic ... of electrons but also on their spin and ... of electric into magnetic signals and vice versa. ... from the Institute of Physics at Johannes Gutenberg ... UK, Prague, and Japan, has for the first ...
(Date:8/28/2014)... 2014   SunTrust Robinson Humphrey (STRH) ... to its equity research team in biotechnology and ... in equity research demonstrates our commitment to providing ... enhance their investment decision making," said Biff ... continue to make significant investments in differentiated content ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:8/29/2014)... shifts over the last 120,000 years may have ... of researchers led by City College of New ... biodiversity metric called "phylogeographic endemism." , It quantifies ... species is restricted in geographical space. , Dr. ... other researchers from institutions in Brazil, Australia and ...
(Date:8/29/2014)... cell,s nucleus, chromosomal DNA is tightly bound to ... call chromatin. Until about two decades ago, histones ... packing material around which the glamorous DNA strands ... greater appreciation for how DNA/histone interactions govern gene ... institutions studying the sequence of the genome from ...
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Yale study identifies possible bacterial drivers of IBD 2
... New York University School of Medicine researchers provide some ... to air pollution--even at levels within federal standards--causes heart ... disease but until now it was poorly understood how ... well-designed mouse study, where animals breathed air as polluted ...
... diseases during in vitro fertilization offers couples the best ... could potentially cause doctors to misdiagnose a small fraction ... Citing concerns about the accuracy of preimplantation genetic diagnosis, ... embryos during IVF, UF researchers set out to study ...
... health hazard, researchers at the University of Rochester Medical Center ... in mice to harm the function of T-cells, which regulate ... , The discovery adds insight to the latest trend in ... public health threat to understanding the long-term burden on the ...
Cached Biology News:Researchers show how air pollution can cause heart disease 2Researchers show how air pollution can cause heart disease 3Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3The dangerous legacy of lead 2
pETDuet-1 is designed for the coexpression of two target genes....
... Recognizes K+ Cl- ... shows no significant sequence ... or CCC.,SPECIES REACTIVITIES: The ... conserved in human, mouse, ...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
oligophrenin-1 (H-100)...
Biology Products: